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1. Introduction
Neuroblastoma (NB) is an embryonic tumour that originates from cells of the neural crest (NC)
arrested in their differentiation at different stages along the sympatho-adrenal lineage and,
less frequently, from precursors of sensory neurons [1, 2]. As a consequence, NB can occur
throughout the sympathetic chain from thoracic, abdominal and pelvic sites to the adrenal
medulla, which accounts for the majority of NBs. Consistent with this, NBs exhibit a high
degree of genetic heterogeneity and biological variability, including differences in catechola‐
mine expression, according to their differentiation state along the sympathoadrenal lineage,
with a small number of primitive midline and spinal NBs that do not secrete catecholamines
considered to be of dorsal root sensory origin [1, 2].
Sympathetic nervous system development is orchestrated by neurotrophins (NT) and their
respective neurotrophin receptors (NTR), which exhibit subtle temporal and spatial changes
in expression that are critical for the delamination, migration, proliferation, survival, differ‐
entiation and apoptotic programs of NC lineages that form the fully differentiated and
functional sympathetic nervous system. Not surprisingly NBs, consistent with their origin and
particular differentiation state at the time of transformation, exhibit a variety of different
patterns of NT and NTR expression. A great deal of research has focussed on characterising
and exploiting these different patterns of expression for potential prognostic and therapeutic
benefit. Recent studies have led to exciting new developments in understanding how block‐
ages in sympathetic differentiation promote NB and how NBs utilise different patterns of NT
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and NTR expression to select a more malignant, stress-resistant, invasive, genetically unstable,
stem cell-like phenotype. Furthermore, they have also identified novel potential therapeutic
targets and characterised patterns of NT/NTR expression of value in prognosis and therapeutic
choice. In this chapter therefore, we will review the origins of NB during neural crest migation
and sympathetic nervous system development, introduce NTs and NTRs and describe their
roles NC and sympathetic nervous system development, examine patterns of NT/NTR
expression in NB, review their potential roles in regulating spontaneous NB regression and
metastatic NB progression, and discuss potential therapeutic ways to target the NT/NTR
system in NB.
2. Formation of the neural crest, neural crest cell delamination and
migration
NBs originate from NC cells (NCC) during sympathetic nervous system development. In this
section therefore, we will briefly describe the natural history of neural crest, sensory dorsal
root and sympathetic nervous system development, focussing attention on the sympatho-
adrenal neuroblast lineage, which is responsible for generating neuroendocrine chromaffin
tissues, SIF and ganglion cells, and in particular the adrenal medulla within which the majority
(40-50%) of NBs develop [2, 3].
Figure 1. Formation of the Neural Crest and Neural Crest cell migration
During  the  3rd  week  of  human  embryonic  development  the  intra-embryonic  mesoderm
differentiates into paraxial, intermediate and lateral plate portions. The paraxial mesoderm
organises into primitive segmented somites and the lateral plate mesoderm splits into somatic
(parietal)  and  splanchnic  (visceral)  layers.  This  event  occurs  in  a  BMP-induced  Notch-
dependent “clock” and Wnt-dependent “wave” manner in a rostral to caudal gradient of
FGF [2, 4-6] and results in the simultaneous formation of Somite pairs either side of the
forming neural tube, in a head to tail direction along the entire length of the embryo, with
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each new somite forming on the caudal side of an existing somite. Somites further differen‐
tiate into dermomyotome and sclerotome structures that will eventually provide the cells for
skin,  muscle  and  skeletal  formation.  Contemporarily,  the  embryonic  neuroectoderm
undergoes progressive indentation to form the neural groove, neural folds and neural plate.
This neurulation process causes the fusion of opposing neural  folds at  the future upper
cervical level, which progresses in both rostral and caudal directions, eventually resulting in
continuity  between  neural  and  squamous  surface  ectoderm.  This  event  separates  the
presumptive epidermis from the neural plate, which in turn forms the distinct and sepa‐
rate columnar cellular structure of the Neural Tube. Interaction between the neural plate and
presumptive epidermis is regulated by Wnts, BMPs and FGFs and results in mesenchymal
transformation of the epithelial cells that line the margins of the neural fold. These cells
organise between the epidermis and neural tube to form the transient Neural Crest (NC)
embryonic structure [2, 6] (Fig. 1).
NC cells (NCC) delaminate from the NC and migrate initially in a ventrolateral manner and
later in a dorsolateral direction, relative to the somites. Ventrolateral NCC migration occurs
in chain-like manner [7] between the somites and neural tube and the rostral half of each somite
[8]. NCC initially migrate through the inter-somitic boundary before switching to a sclerotome
pathway controlled by semaphorin and its receptor neuropilin, with the entire dermomytome
repulsing neuropilin positive trunk NCC [9] (Fig. 2).
Figure 2. Neural Crest cell ventrolateral and dorsolateral migration
Dorsolateral NCC migration occurs between the developing dermis and the dorsal dermo‐
myotome boundary [8, 10]. During NCC migration cells receive signals from adjacent struc‐
tures that initiate a series of differentiation processes that will eventually lead to
differentiation-commitment and specific cell fates at different locations. This process provides
a wide variety of differentiated tissues, including: epidermal pigment cells (melanocytes);
dorsal root, sympathetic and parasympathetic ganglia, neurons and plexuses; neuroglial and
Schwann cells; endocrine/paracrine cells of the adrenal medulla, carotid body and organ of
Zuckerland; cartilage and bones of the facial and ventral skull; corneal endothelium and
stroma; tooth papillae; dermis, smooth muscle and adipose tissue of the head and neck;
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connective tissue of the salivary, lachrymal, thymus, thyroid and pituitary glands and
connective tissue and smooth muscle in arteries of aortic origin (Fig. 3).
Figure 3. Neural crest cell destinations during embryonic development
3. The sympathetic nervous system
The  vertebrate  nervous  system is  composed of  the  central  (CNS)  and peripheral  (PNS)
nervous systems, the former comprised of the brain and spinal cord and the latter com‐
prised of ganglia and associated plexuses that innervate and connect visceral organs and
other tissues to the CNS.
The PNS is divided into the somatic and autonomic nervous systems, the former responsible
for skeletal muscle function and the latter for innervation of visceral organs [11, 12]. The
autonomic nervous system is further subdivided into sympathetic (SNS) and parasympathetic
(PSNS) nervous systems, which are often antagonistic. Motor outflow from both systems is
formed by serially connected neurons that initiate with pre-ganglionic neurons of the brain
stem or spinal chord, which synapse with ganglia and post ganglion neurones outside the
CNS. Parasympathetic ganglia lie close to or within the organs they innervate, whereas
sympathetic ganglia lie at some distance from their target organ. Both have sensory fibres that
feedback information concerning organ function to the central nervous system [11, 13].
The NC is fundamental for SNS formation. Pluripotent migratory NCC progenitors delaminate
from the NC and migrate in a vetrolateral direction through the rostral half of each somite.
NCC remaining within somites coalesce to form paraspinal dorsal root ganglia, which contain
the nerve bodies of afferent spinal nerves responsible for relaying sensory information into the
CNS. NCC that exit somites ventrolaterally initially lose segmental organisation, mix adjacent
to the dorsal aorta then re-segregate to form sympathetic ganglia, helping to explain sympa‐
thetic ganglia heterogeneity [7]. At this point cells initiate differentiation that is responsible
for the eventual formation of sympathetic ganglia, associated sympathetic neurones and
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Schwann cells, small intensely fluorescent (SIF) cells and chromaffin cells of the adrenal
medulla and extra adrenal paraganglia (Fig. 4). Together, these components form the neuro‐
endocrine SNS, which consists of preganglionic neurones that exit from spinal chord ventral
routes of the 12 thoracic and 3 lumbar spinal segments that synapse with neurons of the
sympathetic ganglia or specialised chromaffin cells of adrenal medulla and paraganglia.
Sympathetic ganglia include paravertebral and prevertebral ganglia, with pairs of paraverte‐
bral ganglia each side of the vertebra interconnected to form the sympathetic chain. Normally,
there are 21 to 22 pairs of paravertebral sympathetic ganglia, 3 cervical, 10-11 thoracic, 4
lumbar, 4 sacral and a single ganglion impar in front of the coccyx. Cervical superior, middle
and stellar ganglia innervate viscera of the head and neck, thoracic ganglia innervate viscera
of the trunk, and lumbar/sacral ganglia innervate the pelvic floor and lower limbs. Sympathetic
ganglia also innervate blood vessels, muscle, skin, erector pilli and sweat glands [11, 13].
Figure 4. Cell types generated from differentiated sympathoadrenal neuroblast progentitors
In general, preganglionic neurons utilise acetylcholine as the major neurotransmitter, whereas
post-ganglionic neurons are noradrenergic and utilise noradrenalin as the major neurotrans‐
mitter, combined with specific neuropeptide transmitters (e.g. neuropeptide Y, somatostatin,
vasointestinal peptide and calcitonin related peptide), utilised in an organ-specific manner.
Under normal conditions the sympathetic nervous system provides local adjustments (e.g.
sweating) and relax adjustment to the cardiovascular system. Under conditions of stress, the
entire SNS can activate to induce the “fight or flight” response, during which adrenalin
released from the adrenal gland leads to rapid increases in heart rate, cardiac output, skeletal
muscle vasodilation, cutaneous and gastrointestinal vasoconstriction, pupil dilation, bronchial
dilation and pili-erection, in preparation for imminent danger [11, 13].
3.1. Sympatho-adrenal progenitors, SIF and Chromaffin cells of the neuroendocrine SNS
The vast majority (40-50%) of NBs arise from neuroblastic NCCs within the developing adrenal
gland [2, 3]. Therefore, a description of normal adrenal gland development is also warranted
at this point.
The fully developed functional adrenal gland is composed of cortex and medulla. The adrenal
medulla is composed of neuroendocrine-differentiated chromaffin, SIF and ganglion cells,
which are also present in extra-adrenal paraganglia of the carotid body and organ of Zucker‐
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land [14]. Chromaffin and SIF cells, characterised by their affinity from chromium salts, are
closely related to sympathetic neurons and, like sympathetic neurons, synthesise, store, uptake
and release catecholamines and express enzymes for noradrenalin synthesis including tyrosine
hydroxylase (TH) and dopamine-β-hydroxylase (DBH). Unlike sympathetic neurons, chro‐
maffin cells also synthesise, store and release adrenalin and retain their capacity proliferate
but do not produce axons or dendrites [15]. Adrenal and extra-adrenal chromaffin tissues, like
sympathetic ganglia, are innervated by pre-ganglionic neurones originating from the spinal
chord [16]. Chromaffin, SIF and sympathetic neurons exemplify the wide spectrum of
sympathoadrenal cell types that originate from NCC [17].
Chromaffin and SIF cells differentiate from pluripotent NCC progenitors that delaminate from
the NC at the “adreno-medullary” somite level (somites 18-24 in avian development) [18].
These cells migrate ventrolaterally initially between Somite dermomyotome and sclerotome
then through the rostral sclerotome mesenchyme to arrive at para-aortic sites [18-20]. At these
sites, NCC mix, re-segregate and coalesce to form sympathetic ganglia. At the same time, NCC
derived from the “adreo-medullar” somite region coalesce adjacent to the adrenal cortex
anlage then invade the anlage in considerable numbers, initially in a nerve fibre-independent
then nerve fibre-dependent manner [21], in a Sox transcription factor-dependent manner [22].
Once within the adrenal primordium, NCCs form rosettes, nests and nodules along nerve
fibres, proliferate and initiate pheo-chromoblast differentiation. This process continues
throughout foetal development and into the neonatal period, providing differentiated
Chromaffin and SIF adrenal medulla cell populations. In humans, the gestational period
between 17 and 20 weeks is critical for adrenal sympathetic component development, with
neuroblastic NCC proliferation peaking during this period in terms of maximal nodule size
and number, waning thereafter. Neuroblastic nodules tend to disappear during the third
trimester and are usually absent at birth. However, nodules that continue to grow and persist
into neonatal life are not infrequent and have been classified as in situ NB. A sizeable number
of these NBs spontaneously regress and are likely, therefore, to represent delayed differentia‐
tion in addition to neoplastic transformation [23].
Chromaffin cells, SIF cells and sympathetic neurons develop from catecholaminergic sympa‐
thoadrenal (SA) progenitors [18, 24, 25] and their formation involves BMP signalling [18,
26-28]. However, the classical concept that a common SA lineage acquires neuronal and
catecholaminergic traits prior to migration to secondary sympathetic ganglia and adrenal sites
[24, 25] has now been discounted, as chromaffin cells undergo catecholaminergic differentia‐
tion within the adrenal anlage and not within primary sympathetic ganglia, and do not express
neuronal markers at the onset or even following induction of TH expression [29, 30]. Therefore,
sympathetic neuronal and chromaffin lineages must separate upstream prior to catecholami‐
nergic differentiation, despite evidence of sympathoadrenal marker expression in some
migrating cells [22, 24, 30], and enter the adrenal primordium as undifferentiated Sox10
expressing NCC [22, 30]. Indeed, chromaffin and sympathetic neurones originate at the same
axial level from common NC progenitors but differ in the time of catecholaminergic differen‐
tiation [18]. Furthermore, NCC populations migrating to the adrenal anlage and within the
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adrenal medulla exhibit heterogeneity, and consist of SOX10/Phox2B/p75NTR, SOX10/
p75NTR and PHox2B/p75NTR sub-populations [22].
3.2. Transcriptional regulation of sympathoadrenal differentiation
Chromaffin and sympathetic neuron differentiation is regulated by BMP-induced transcrip‐
tion factors Phox2B, Mash-1,  Insm1, Hand2 and Gata 2/3 [31].  Knockout technology has
identified a fundamental role for Phox2B in chromaffin and sympathetic neuronal differen‐
tiation [18], with Phox2B knockout increasing neuron but not chromaffin precursor death.
This not only relates to specific cell traits but also differences in environment and migra‐
tion  [32,  33],  and  confirms  that  adrenal  anlage  are  colonised  by  undifferentiated  NCC
progenitors. Knockout technology has also characterised a role for Mash-1 as an accelera‐
tor of sympathetic neuronal and chromaffin differentiation [34, 35], a role for Insm-1 as a
regulator  of  catecholamine  synthesising  enzyme  expression  and,  therefore,  endocrine
differentiation [36, 37], a role for Hand2 in the induction and maintenance of noradrener‐
gic differentiation [38, 39] and a role for Gata3 in the differentiation of both sympathetic
ganglia and chromaffin cells [31, 40].
It has now been confirmed that adrenal cortex glucocorticoids are not responsible for chro‐
maffin cell differentiation [41] but they do, however, regulate postnatal chromaffin cell
survival and phenyl ethanolamine N-methyl transferase expression [30, 42]. The adrenal cortex
is also dispensable for chromaffin differentiation, which is also found in extra-adrenal
neuroendocrine tissue, but may regulate adrenal chromaffin cell numbers and associated
vascularity [30, 43]. Within the adrenal gland, hypoxia has recently been shown to promote
chromaffin/SIF cell differentiation from neuroblasts [44-46].
4. Neurotrophins and neurotrophin receptors in neural crest, sympathetic
nervous system and adrenal development
Neurotrophins (NTs) and NT receptors (NTRs) are critical for the development and mainte‐
nance of the vertebral CNS and PNS [47-50], NTs and NTRs are also expressed by human NBs
and have been implicated in both NB regression and malignant progression. In this section,
therefore, we will introduce NTs and NTRs and describe their potential involvement in normal
SNS and adrenal development.
4.1. Neurotrophins (NTs)
NTs are a family of growth, differentiation, survival and apoptosis-inducing factors that are
involved in many aspects of nervous system development, maintenance and function. They
comprise four structurally related basic 115-130 amino acid containing polypeptides, nerve
growth factor (NGF), brain-derived growth factor (BDNF), and the neurotrophins 3 (NT-3)
and 4/5. NGF was first NT to be described and purified from the mouse salivary gland [51].
This was followed by the discovery of BDNF, NT-3 and NT-4/5 some 30 years later [52-54].
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NTs exhibit close structural homology, with the exception of NT4/5 that exhibits only 50%
homology to the others NTs, and all contain six conserved cysteines that form structurally
important disulphide bridges [55, 56]. NTs are expressed by both neuronal and non-neuronal
cells as pre-NTs and are converted to pro-NTs upon signal peptide removal. This can occur
within the endoplasmic reticulum (ER), in which NTs are converted to mature-NTs by furins.
Alternatively, NTs are transported to the cell surface and released following signal peptide
removal as pro-NTs. Secreted pro-NTs, which also exhibit biological activity, are converted to
mature NTs by enzymes including plasmin and the matrix metalloproteinases MMP-7 and
MMP-9 [56-58]. Within the extracellular environment, pro- and mature NTs form homo-dimers
and bind specific receptors to induce an array of biological activities, including cell migration,
proliferation, survival, differentiation, apoptosis and neuronal synapse/junction plasticity,
depending upon the cell population, receptor expression and activation status [57, 60]. The
human NGF gene localises to chromosome 1p13.1 [61], the human BDNF gene localises to
chromosome 11p13 [62], the human NT-3 gene localises to chromosome 12p13 [62] and the
human NT4/5 gene localises to chromosome 19q13.3 [63]. Since the discovery of NTs, their
respective receptors have been identified and many of their roles in nervous system develop‐
ment and function have been elucidated.
4.2. NT receptors
4.2.1. Tropomyosin-related kinases TrkA, TrkB and TrkC
The family of NT receptors includes the tropomyosin-related tyrosine kinases TrkA, TrkB and
TrkC [64]. TrkA is the preferred receptor of mature NGF but also binds the mature neurotro‐
phin NT-3 [64, 65]. Identified following the discovery of the first tumour-associated TrkA
oncogene [64, 66, 67], the 25kb human TrkA gene maps to chromosome 1q21-22 and is
organised into 17 exons [68-70]. TrkA proteins are expressed either as the fully spliced
gp140kDa TrkAII receptor, alternatively spliced TrkA L0 and L1 variants that exhibit differ‐
ential exon 2-4 use [71], the TrkAI variant that exhibits exon 9 skipping [72] or the TrkAIII
variant, which exhibits in-frame skipping of exons 6 and 7 combined with exon 9 omission [73].
TrkA L0 (exons 2, 3 and 4 alternatively spliced) and TrkA L1 (exons 2 and 3 alternatively
spliced) are expressed during rat development [71] as truncated receptors with in-frame
deletions of leucine-rich sequences encoded within exons 2-4 [68]. Since, TrkA leucine rich
sequences may modulate ligand binding [74], these variants may exhibit altered ligand-
binding activity similar to analogous alternative TrkB splice variants [75]. TrkAI (exon 9
exclusion) and TrkAII (exon 9 inclusion) splice variants [72] are expressed as cell surface trans-
membrane receptors and exon 9 omission does not result in ligand-independent receptor
activation. TrkAI and TrkAII variants bind NGF and NT3 [72, 76] but TrkAII exhibits higher
levels of NT-3-mediated activation when co-expressed with the low affinity neurotrophin
receptor CD271/p75NTR [76]. TrkAII is predominantly expressed within the nervous system,
whereas TrkAI expression predominates in the thymus [72].
TrkAIII was identified as an unexpected RT-PCR product in primary human NBs [73]. This
variant exhibits exon 6 and 7 skipping plus exon 9 omission, resulting in the in-frame deletion
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of amino acids 192-284 that encode the D4 extracellular immunoglobulin-like domain, several
functional N-glycosylation sites and introduces a valine substitution at the novel exon 5/8
splice junction [73]. In addition to being expressed by primary human NBs, TrkAIII is also
developmentally regulated and is detected from stages E13-E18 of mouse embryonic devel‐
opment and is also expressed by immature thymocytes within the developing thymus [73,
77]. Unlike fully spliced TrkA receptors, TrkAIII is not expressed at the cell surface but is
retained within intracellular membranes of the endoplasmic reticulum (ER), GN and ER/GN
intermediate compartment (ERGIC) [73, 78, 79], within which it exhibits interphase-restricted
spontaneous ligand-independent activation [73, 78, 79].
TrkB is the preferred receptor of BDNF but also binds NT-4/5 [65, 80-82]. The 590kb human
TrkB gene maps to chromosome 9q22 and contains 24 exons [70, 83]. In addition to fully spliced
gp145kDa TrkB, eight TrkB variant isoforms have been described, including a gp95kDa C-
terminal truncated receptor that lacks the tyrosine kinase and Shc binding domains; a C-
terminal truncated receptor that lacks the tyrosine kinase domain but retains the Shc binding
site; a C-terminal truncated receptor that lacks exons 23 and 24 but retains tyrosine kinase
activity and four N-terminal truncated receptors that exclude combinations of exons 1-5 and
upstream signal sequence [75, 83-85]. The TrkB gene has also been reported to encode up to
100 different transcripts ranging from 0.7-9kb, at least 36 of which can be translated into
functional TrkB proteins [85-87]. Both full length and C-terminal truncated TrkB receptors are
expressed in the brain and share 100% extracellular domain homology, consisting of 5 highly
glycosylated extracellular binding domains (D1-5) [75, 85, 86].
TrkC binds NT-3 and no other NT [88]. The 387kb human TrkC gene maps to chromosome
15q25 and is organised into 18 exons [70] and six TrkC isoforms have been described. In
addition to the fully spliced gp145kDa receptor, these isoforms include C14/K2, C25/K3 and
C39 variants which contain 14, 25 and 39 additional amino acid insertions between kinase
subdomains VII and VIII, downstream of the TDYYR motif of the putative Trk receptor family
autophosphorylation site [89] and NC1/T1 and NC-2/T2 non-catalytic variants truncated in
the tyrosine kinase domain by short C-terminal sequences [90-92]. Full-length TrkC receptors
are expressed during development, whereas truncated receptors predominate in later life in
post mitotic cerebellar granule neurons and young stem cell-derived differentiated neurons
but not in proliferating neural stem cells. TrkC NC1/T1 and NC2/T2 variants do not support
NT-induced neuritogenesis, suggesting that TrkC variants could exert different roles during
nervous system development [90, 93].
4.2.2. CD271/p75 neurotrophin receptor
The p75 neurotrophin receptor (CD271/p75NTR) is a member of the tumour necrosis factor
(TNFR)/FAS receptor superfamily and binds all NTs in pro-form with high affinity and mature
NGF with low affinity [94, 95]. The 3.4kb CD271/p75NTR gene is organised into 5 exons and
maps to chromosome 17q21-q22 [96]. In addition to the fully spliced 75kDa CD271/p75NTR
receptor, a truncated alternative s-p75NTR splice variant has been described that is devoid of
exon III. S-p75NTR lacks the NT binding domain, does not bind NTs and is expressed by several
neural tissues [97]. The fully spliced CD271/p75NTR extracellular-domain contains four 40-
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amino acid repeats with 6 cysteine residues at conserved positions that are required for NT
binding, a serine/threonine-rich region, a single transmembrane domain and a 155-amino acid
cytoplasmic domain, which does not exhibit catalytic activity. CD271/p75NTR acts either as an
independent NT receptor, a NT receptor complex with Sortilin or a co-receptor for TrkA, and
is involved in regulating death, differentiation or survival signals [94, 98]. The CD271/P75NTR
receptor is devoid of intrinsic catalytic activity, indicating that signalling from this receptor
must depend upon intracellular interactors [99, 100].
4.2.3. Sortilin
Sortilin is a member of the Vps10p domain-containing transmembrane proteins that binds both
mature NGF and the neurotrophins NGF, BDNF and NT-3 in pro-form [98, 101, 102]. The 7kb
human Sortilin gene localises to chromosome 1p13.3 and is expressed as a gp95-100kda
glycoprotein [103, 104]. Sortilin co-expression with CD271/p75NTR results in the formation of a
co-receptor complex that augments affinity for proNGF and acts principally as an inducer of
apoptosis [105].
4.3. NT receptor structure and ligand binding
All three Trk receptors share significant sequence homology and a conserved domain organ‐
ization. This organization comprises from N-terminus to C-terminus of five extracellular
domains, a transmembrane region and the intracellular kinase domain.
Figure 5. NT receptor structure and ligand binding domains
The first three extracellular domains consist of a leucine-rich region (D-2) flanked by two
cysteine-rich regions (D-1 and D-3), and domains 4 and 5 are immunoglobulin-like domains.
Studies on TrkB and TrkC have shown that D-5 is sufficient for the binding of ligands and is
responsible for binding specificity [106-109], although the D-4 domain, leucines and cysteine
clusters may regulate ligand binding [55, 73]. Receptor transmembrane and juxta-membrane
regions are critical for signal internalisation and transduction. The intracellular tyrosine-rich
carboxyl terminal cytoplasmic domain exhibits tyrosine kinase activity upon ligand-mediated
activation and is responsible for propagating post-receptor signal transduction [74, 107,
110-114]. The immunoglobulin-like D4 and D5 domains stabilise receptors in monomeric form
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and prevent spontaneous receptor oligomerisation and activation. Deletions, chimeric
receptors and point mutations that disrupt the structure of the first (D4) and second (D5)
immunoglobulin-like domains result in ligand-independent spontaneous receptor activation
and the acquisition of oncogenic activity [73, 110, 115] (Fig. 5).
CD271/p75NTR receptors modulate the affinity and enhance the specificity of TrkA for NGF,
and TrkB for BDNF, with optimal affinity reflecting the ratio of Trk to CD271/p75NTR receptors
[116-118]. In contrast, CD271/p75NTR reduces TrkAI activity in response to NT-3 and TrkB
activity in response to NT-3 and NT-4/5 [76, 119, 120]. The CD271/p75NTR receptor analogue
neurotrophin-related homolog-2 (NRH2) that is expressed by neural cells, also interacts with
TrkA to promote high affinity NGF binding [121].
4.4. NT receptor signalling
In the absence of ligand, Trk receptors are maintained as inactive oligomers [120], concentrated
within caveolin and cholesterol-containing cell membrane caveolae invaginations, which also
contain components of the Ras signalling pathway [122]. Receptor oligomers are maintained
in an inactive state by mature extracellular domain N-glycosylation, intact D4 and D5 domains
and by receptor-associated protein tyrosine phosphatases (PTPases) [110, 123-126]. Upon
ligand binding, oligomeric Trk receptors dimerize, alter their conformation and acquire
tyrosine kinase activity, facilitated by temporary inactivation of receptor-associated PTPases,
which results in auto- and trans-phosphorylation of receptor tyrosine residues Y490, Y670,
Y674/675, Y751 and Y785, in TrkA and their equivalents in TrkB and TrkC. These tyrosines act
as phosphorylation-dependent binding sites for a variety of signalling proteins, including the
adapters Shc and FRS-2; Grb-2 and SOS; the IP3K subunit p85α and PLCγ. These interactions,
which are modulated by CD271/p75NTR, provide avenues for signal transduction through RAS/
MAPK, IP3K/Akt/NF-κB and PKC pathways that mediate NT effects upon migration, prolif‐
eration, survival, differentiation and apoptosis [73, 111, 127-141]. Cell surface Trk localisation
and NT-mediated Trk activation also involves interaction with the heat shock protein chap‐
erone Hsp90 [78].
 
Figure 6. Trk receptor signalling and outcome
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Trk receptors activated by NTs use two main pathways to activate MAPKs. The first pathway
involves Shc, Grb-2, SOS, Ras and Raf, and the second pathway involves CrkL, Rap and Raf
[142, 143]. Trk activation of MAPK is now considered to depend not only upon the phos‐
phorylated Trk Y490 tyrosine residue [144, 145] but also the ankyrin repeat-rich membrane
spanning protein ARMS, acting through CrkL [146, 147]. MAPKs activate CREB transcription
factors to promote differentiation and survival [148-150]. Trk activation of PI3K/Akt signalling
occurs through Shc/Grb-2 and Gab-1 and induces pro-survival signals [73, 151, 152], resulting
from the phosphorylation of Bad and activates the pro-survival transcription factor NF-κB [73,
153, 154]. PLCγ is activated as a consequence of being recruited to the phosphorylated Trk
tyrosine Y785 [73, 132] and provides additional differentiation and survival signals that
involve MAPK [155] (Fig. 6).
The alterative TrkAIII splice variant, in contrast to other Trk receptors (see above), is not
expressed at the cell surface but accumulates within intracellular membranes. Intracellular
TrkAIII does not bind extracellular NTs and is prone to spontaneous ligand-independent
intracellular activation [73, 78, 79]. In contrast to ligand activated cell surface TrkA signalling,
spontaneously active TrkAIII signals through PI3K/Akt/NF-κB but not Ras/MAPK, resulting
in increased survival and the induction/maintenance of a stem cell-like undifferentiated
phenotype [73, 78, 79, 156] (Fig. 6).
An additional feature of TrkA receptors is retrograde transport signalling within the cell. This
depends upon receptor/ligand interaction, internalisation and retrograde transport of activat‐
ed receptors, resulting in signal transduction within the cell body. Sympathetic neurons most
dramatically illustrate this activity, with retrograde transport of NGF-activated TrkA occur‐
ring along the axonal length to the neuronal cell body. This phenomenon involves ubiquitin
mediated receptor internalisation through interaction with CD271/p75NTR and TRAF6, receptor
endocytosis within clatherin-coated vesicles and receptor endocytosis facilitated by the
endocytosis inducing protein EHD4/Pincher [157-159]. In addition, immature Trk receptors
also localise to intracellular membranes of the Golgi Network (GN) and can be trans-activated
by agonists of the G-protein linked A2A adenosine receptors, potentially through the non-
receptor tyrosine kinase Src [160, 161], providing evidence for intracellular neurotrophin-
independent Trk activation. Post receptor signal transduction from GN-associated TrkA
differs from cell surface-activated TrkA, by signalling through IP3K/Akt but not RAS/MAPK,
which results in NF-κB transcription factor activation, inducing a more stress-resistant
phenotype, not dissimilar to that induced by the intracellular alternative TrkAIII splice variant
[73, 124, 160]. TrkA localisation to the GN may not only reflect transient passage of de-novo
synthesised receptors but also alterations in receptor extracellular domain N-glycosylation and
folding.
CD271/p75NTR receptors regulate cell survival, apoptosis, differentiation and proliferation.
CD271/p75NTR is a positive modulator of Trk-mediated survival, and within this context, it is
likely that CD271/p75NTR does not directly bind NTs in competition with Trks [162] but acts as
a co-receptor, interacting with Trk dimers ligated to active NTs, refining receptor specificity
(e.g. increasing specificity for NGF, while restricting NT-3 binding) [163]. This may be
responsible for shifting NT dependence during development coincident with CD271/p75NTR
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 expression, which is exemplified by the shift from NT-3/TrkC to NGF/TrkA dependence
observed during SNS development [164]. CD271/p75NTR may also influence Trk signalling by
binding of the Shc adapter, which also binds to activated Trk, to augment or inhibit Trk
signalling [165, 166], and in Trk-complexed form may result in different signalling to that from
Trk dimers alone [147], resulting in differences in capacity to complete differentiation pro‐
grams [167] (Fig. 7).
As a pro-apoptotic receptor CD271/p75NTR also exhibits Trk-independent activity. The
cytoplasmic tail of CD271/p75NTR contains death domains and its role in apoptosis has been
clearly demonstrated in CD271/p75NTR exon 3 knockout mice [168]. CD271/p75NTR exon 3
knockout mice combined with TrkA knockout mice have highlighted the dual function for
CD271/p75NTR in refining innervation and eliminating neuronal excess during early develop‐
ment and later in neuronal survival [169, 170]. Apoptosis induced by CD271/p75NTR involves
JNK, phosphorylated c-jun, p53, Bad, Bim and activated caspases [168, 169, 171-174]. Apoptosis
induced by CD271/p75NTR may also involve β-secretase-mediated release of the intra-cyto‐
plasmic domain, its subsequent nuclear transport and potential involvement in transcriptional
regulation, together with TRAF6, NRAGE, NADE, NRIF and SC-1. TRAF6 interaction with
NRIF has been implicated in the generation of death signals through the activation of JNK
[169, 175]. NRAGE interaction with CD271/p75NTR is involved in inducing cell death through
JNK and caspase activation, and is blocked by TrkA [176]. A role for NADE in CD271/p75NTR–
mediated apoptosis, involving NGF but not BDNF or NT-3, has been reported [177], whereas
CD271/p75NTR interaction with SC-1 has been implicated in cell cycle arrest via transcriptional
repression of cyclins [178] (Fig. 7). Further advances in the understanding of this effect have
come with the observation that inactive pro-form NT precursors bind CD271/p75NTR receptors
with high affinity and trigger apoptosis at far lower concentrations than active counterparts,
which bind with low affinity (Lee et al., 2001). Up to 60% of NTs released by cells are proform
[56]. Indeed proNGF induces death in CD271/p75NTR expressing cells, highlighting an opposite
effect to activated NGF in cells, including sympathetic neurones [56]. The capacity of proNGF
to activate CD271/p75NTR but not TrkA is now known to depend upon Sortilin, a 95kDa member
Figure 7. CD271/p75NTR receptor signalling and outcome
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of the Vps10p-domain receptor family [98, 101]. In this interaction, complexes between CD271/
p75NTR and Sortilin are augmented by proNGF, which simultaneously binds both receptors to
induce apoptosis. Thus Sortilin acts as an essential co-receptor capable of switching cells that
co-express TrkA and CD271/p75NTR from survival to apoptosis.
CD271/p75NTR receptors, therefore, promote either survival or death in response to NTs,
depending upon NT status and the cellular context. Survival through CD271/p75NTR receptors
involves NF-κB activated through TRFA6, p62, Interleukin-1 receptor-associated kinase IRAK
and receptor interacting protein RIP2 [179]. CD271/p75NTR promotion of axon growth involves
neurotrophin-mediated dissociation of axonal growth inhibitory complexes between
CD271/p75NTR and the G-protein Rho [180]. Furthermore, the proteolytic shedding of cell
surface CD271/p75NTR releases an intracellular domain that moves to the nucleus and may act
as a transcription factor [181].
4.5. Trks A and C are dependence receptors
A classical concept is that NT activation of Trk receptors inhibits default apoptotic programs
to promote NT-dependent survival [134]. This concept is considered to involve PI3K/Akt/NF-
κB signalling and induction of Bcl-2 inhibitor of mitochondrial apoptosis. In this mechanism,
NT depletion results in the turning-off of PI3K/Akt signalling, which reduces Bad phosphor‐
ylation and releases it from the chaperone 14-3-3. This results in Bcl-2 and Bcl-XL sequestration
[182, 183], reduces FOX03A phosphorylation resulting in nuclear translocation, induces pro-
apoptotic FAS, Trail, Puma and BIM transcription [184-188], abrogates CREB and NF-κB
survival signals [189, 190] and activates pro-apoptotic JNK, inducing BIM expression [188],
which together trigger apoptosis (Fig. 8).
 
Figure 8. TrkA and TrkC receptors and Apoptosis
Recently, however, both TrkA and TrkC have also been characterised as true dependence
receptors. In one study, TrkC but not TrkA or TrkB triggered apoptosis in the absence of NT-3
in a variety of cell lines by an activated caspase-dependent cleavage mechanism, releasing a
pro-apoptotic intracellular TrkC domain capable of inducing caspase-9 dependent death [191].
Neuroblastoma60
In a separate study, TrkA and TrkC but not TrkB induced apoptosis in neurons differentiated
from stable transfected embryonic stem cells and promoted loss of all TrkA and TrkC but not
TrkB transfected cells with associated loss of nervous system at E13.5 during mouse embryonic
development, through a CD271/p75NTR -mediated mechanism, in which CD271/p75NTR is
recruited as a “hired killer” [192]. Therefore in the absence of ligand, TrkC acts directly as a
death receptor and TrkA death receptor activity appears to depend upon CD271/p75NTR,
whereas TrkB does not exhibit death receptor activity (Fig. 8)
5. NTs and NTRs in sympathetic nervous system development
5.1. TrkC and NT–3
TrkC is the only NT receptor expressed during early embryogenesis. During avian develop‐
ment TrkC expression coincides with neurulation and is detected in both neural tube and
neural plate anlage [193, 194]. TrkC is also expressed in hindbrain rhombomeres 3 and 5. This,
however, does not associate with lateral NCC migration, suggesting that either TrkC positive
NCC cells die prior to NCC migration or that they migrate away from these regions. NT-3
expression is low at this time and the recent characterisation of TrkC as pro-apoptotic de‐
pendency receptor, supports the former hypothesis [191, 192]. Neither TrkC nor NT-3 knock‐
out prevent neurulation but do result in neuronal loss from sympathetic ganglia [195-197],
indicating that TrkC/NT-3 interactions are not required for neurulation but are required for
later stages of SNS development. Consistent with this, the NT-3 protein is detected at later
developmental stages. There have been no reports concerning the expression of alternative
TrkC isoforms during early development.
During PNS formation, TrkC is expressed by neurogenic pre-migratory and migrating NCC
subsets [194, 198, 199] and TrkC/NT-3 interactions are required prior to NCC arrival at
destination [200]. Indeed, NT-3 acts as a NCC survival factor and promotes NCC proliferation
in the presence of somites [201]. Furthermore, somites express NT-3 during this period [198,
202], sympathetic neuroblasts and neurons also express TrkC and NT-3, NT-3 is expressed by
non-neuronal sympathetic cells [194, 199, 203], and NT-3 and TrkC expression during this time
is stimulated by neuroregulin, PDGF and CNTF [204]. NT-3 in sympathetic tissues increases
mature neuron numbers by promoting the survival of proliferating neuroblast and their
subsequent differentiation, without directly effecting proliferation [205]. This temporary effect
subsequently declines with a switch to NGF-dependence [206], associated with reduced TrkC
expression and the induction of TrkA and later CD271/p75NTR expression [204, 207]. NT-3
continues to be expressed by both sympathetic neural and non-neural cells [198, 199, 204], by
adult non-neural cells [208] and TrkA expression is regulated in part by NT-3 [207]. Therefore,
NT-3 acts as both a survival and differentiating factor through TrkA, eventually rendering
differentiating post-mitotic neurons dependent upon NGF produced by effector tissues. NT-3,
at this stage, acts as an autocrine interim and not peripherally derived paracrine factor,
corroborated by the lack of target innervation at this time [207]. In support of this, NT-3
knockout mice exhibit sympathectomy [106, 197, 209-212] caused principally by neuroblast
Neurotrophin and Neurotrophin Receptor Involvement in Human Neuroblastoma
http://dx.doi.org/10.5772/55536
61
apoptosis, which is partially rescued by exogenous NGF [212]. In the adult, NT-3 continues to
be expressed by a wide range of tissues [202, 203, 213, 214] and, together with NGF, continues
to be important for post-natal sympathetic neuron survival [214, 215]. Consistent with this,
exogenous NT-3 promotes target organ sympathetic innervation in NT-3 knockout animals
[211, 212], suggesting that the switch from NT-3 to NGF dependence observed in sympathetic
neurons in vitro [216] does not actually occur in vivo. This may relate to environmental
differences, corroborated by the mitogenic effect of NT-3 on neuroblasts in vitro [201] but not
in vivo [217], the susceptibility of TrkC transcription to environmental factors and also by the
capacity of NT-3 to bind and activate TrkA receptors, and in particular TrkAII [76]. This helps
to explain how NT-3 rescues NGF-dependent neurons from NGF depletion and vice versa and
is consistent with the characterisation of TrkA as a functional NT-3 receptor in vivo. However,
one difference between these two NTs is that exogenous NGF but not NT-3 induces sympa‐
thetic ganglia hyperplasia [218].
NT-3 released from effector tissues and acting through TrkA also promotes sympathetic
innervation of target organs [202, 213, 214, 219, 220]. In support of this, effector tissue elimi‐
nation induces the death of innervating neurons, which cannot be completely reversed by
exogenous NGF alone, and adult sympathetic neurons expressing TrkA are immunoreactive
for both NGF and NT-3 [49, 221, 222]. Therefore, NT-3 plays an important role throughout
sympathetic neuron life-cycle from neuroblast to neuron, acting initially through the TrkC
receptor as an autocrine/paracrine factor stimulator of migration and survival in proliferating
sympathetic neuroblasts and later as a paracrine promoter of sympathetic neuron differentia‐
tion, survival and target organ innervation acting through the TrkA receptor. CD271/p75NTR
is also required for optimal neurotrophin sensitivity since CD271/p75NTR deficient dorsal root
and sympathetic neurons exhibit reduced sensitivity to NGF [223].
During sympathoadrenal development, progenitors switch from being dependent upon NT3
and TrkC to dependence upon NGF and TrkA, through an intermediate stage of combined
TrkA and TrkC expression. In murine thoracic sympathetic ganglia TrkC expression alone is
detected at E14-15, whereas both TrkA and TrkC expression are detected at E16.5-17 and only
TrkA at E19.5 [224]. Interestingly, sympathetic chromaffin tissues of the adrenal medulla and
paraganglia, which form in parallel to sympathetic ganglia, exhibit differences in NT receptor
expression consistent with upstream progenitor separation. This difference is characterised by
the expression of TrkC but not TrkA by NCCs migrating into the adrenal anlage, at times when
TrkC expression is lost in associated with the induction of TrkA expression by NCCs within
sympathetic ganglia [225].
5.2. TrkA and NGF
Unlike TrkC, TrkA is not expressed during neurulation, NC development or NCC dorsolat‐
eral or vetrolateral migration. In rodent development, TrkA is detected at E12.5 within sensory
cranial and spinal dorsal root ganglia and subsequently in the paravertebral sympathetic
ganglia [226]. NGF is expressed during the mid-stage of development initiating within CNS
structures then within PNS structures at later stages of development [227, 228]. Within the
developing adrenal gland NGF exhibits a brief period of post-natal expression, whereas NT-3
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is expressed by both the developing and adult adrenal gland [229]. This suggests that TrkA/
NGF interactions are of transient importance in adrenal gland development. Consistent with
this,  both  TrkA  and  NGF  knockout  mice  exhibit  a  relatively  normal  adrenal  medulla
chromaffin cell content, although cholinergic innervation of pre-ganglionic origin is lost in
TrkA knockout animals [230], and both chromaffin and SIF cells express TrkA but do not
depend upon NGF for survival. Normal NCC progenitors entering the developing adrenal
glands express TrkC and begin to express TrkA upon seeding under the influence of the
adrenal environment. This event may depend upon NT-3 and/or NT4/5 expressed by the
adrenal cortex anlage, with subsequent chromaffin/SIF differentiation and survival regulat‐
ed by these NTs. In contrast, sympathetic neurones in paravertebral sympathetic ganglia,
despite  their  common  origin,  express  TrkA  and  require  NGF  for  their  development,
differentiation and survival [229-231]. In support of this, NGF neutralising antibodies do not
delay  adrenal  development  nor  induce  chromaffin  cell  degeneration  [232].  Differences
between human and rodent adrenal development include observations that the adult rat
adrenal cortex but not medulla express TrkB or TrkC [229, 230], whereas TrkA immunoreac‐
tivity is restricted to the adrenal cortex and TrkC immunoreactivity to the adrenal medulla
with no TrkB immunoreactivity detected in the human adult adrenal glands [233]. Interest‐
ingly, stress induces a massive release of NGF from salivary glands, which targets adrenal
chromaffin  cells  inducing  marked  adrenal  medullary  hyperplasia  and  catecholamine
synthesis  through  enhanced  TH  and  BDH  expression  [234-236].  In  chromaffin  tissues,
sympathoadrenal cells of the carotid body express NGF and TrkA, providing an autocrine/
paracrine  mechanism  [237].  Pre-natal  and  post-natal  differentiating  and  differentiated
chromaffin cells express TrkA mRNA within the adrenal medulla [238], which increases with
development, at times when NGF expression is all but absent [229]. TrkA knockout elimi‐
nates the acetylcholine positive component but does not influence chromaffin content of the
adrenal medulla [230], indicating that chromaffin cells, unlike their sympathetic neuronal
cousins, do not depend upon NGF/TrkA interactions for survival [232, 239]. Chromaffin cells
do, however, respond to NGF with acute hyperplasia [235] and eventual neuronal differen‐
tiation [240,  241].  In rodents,  immature sympathoblasts  within sympathetic  ganglia  cells
express TrkA from E14 onwards and express CD271/p75NTR from E16 to birth, in associa‐
tion with acquisition of NGF-responsiveness [242]. Differentiated neurons within sympathet‐
ic ganglia express TrkA but not NGF [208].
5.3. TrkB, BDNF and NT4/5
TrkB, like TrkA, is also not expressed during neurulation but is expressed by motor progenitors
in hindbrain rhombomere 2 at later stages 9-10 and 12, during avian development, either side
of the floor plate in the caudal midbrain, extending through the hindbrain and into the spinal
chord [193]. Alternative TrkB splice variant expression has not been assessed during early
development.
Following neurulation, TrkB expression is detected within motor neuron progenitors of the
ventral neural tube and corresponds to BDNF expression by elements within dorsal neural
tube, which coordinate motor neuron development [243]. Consistent with this, both TrkB and
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BDNF knockout mice exhibit the loss of motor and sensory neurons from dorsal root, trige‐
minal, nodose/petrosal, vestibular, and geniculate ganglia [244].
During SNS development, TrkB exhibits expression restricted to sub-populations of pre-
ganglionic cells [230, 245], and sympathoblasts within coalescing sympathetic ganglia, which
exhibit transient TrkB expression prior to differentiating [225]. Sympathoblasts that express
TrkB within coalescing sympathetic ganglia are non-proliferating but do proliferate in
response to BDNF in vitro, suggesting that the concentration of BDNF within coalescing
sympathetic ganglia is sub-threshold at this time [225]. Pre-ganglionic cells respond to BDNF
expressed and release by effector tissues, resulting in pre-ganglionic innervation [230]. Within
the adrenal gland, chromaffin cells express NT4/5 but not TrkB, which is weekly expressed by
the adrenal cortex, providing a neurotrophic source for extra-adrenal TrkB expressing pre-
ganglionic neurons located in spinal chord segments T7-T10. Thes cells use adrenal medullary
NT-4/5 to project axons into the adrenal medulla in a TrkB-dependent manner [230]. BDNF,
on the other hand, is expressed by sympathetic neurones and regulates sympathetic synaptic
complexity [246].
The fact that NT4/5 but not TrkB is expressed within the developing adrenal medulla [230, 238,
247] has prompted hypotheses that medullary NT-4/5 may also ligate and activate TrkA
receptors expressed by adrenal medullary neuroblasts and chromaffin cells [63, 80, 229, 230].
However, adrenal medullary chromaffin tissues do exhibit rapid stress-induced TrkB expres‐
sion, which facilitates the adrenal catecholamine response to stress-induced elevation of blood
bourn BDNF [248].
5.4. CD271/P75NTR
CD271/p75NTR is a neural crest marker that is expressed by NC crest stem cells during early
development, by NC stem cells in peripheral neural tissues during late development after NCC
migration has ceased, and by nerve associated post natal and adult NC stem cells [249]. CD271/
p75NTR expressing adult NC stem cells have been identified as a potential origin for adult
tumours of the PNS and NC, including adult NB [249, 250]. Within the human foetal adrenal
medulla, CD271/p75NTR immunoreactivity is detected in nerve fibres and primitive neuroblast
clusters, and in the adult adrenal medulla is detected in nerve fibres, ganglion cells and
connective tissue cells of septi but not chromaffin cells [251, 252]. CD271/p75NTR is required for
normal sympathetic neuronal death and the death of damaged neurons [253-255]. CD271/
p75NTR knockout alters synapses within sympathetic ganglia and reduces sympathetic target
organ innervation, consistent with its function in enhancing NT-responsiveness [223, 256].
6. Neurotrophins and neurotrophin receptors in human neuroblastoma
6.1. TrkA and NGF expression in NB
The cloning of the TrkA receptor in 1991 [113] initiated the study of TrkA expression in
human NBs [257]. This initial report detected an inverse relationship between TrkA mRNA
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levels and N-myc amplification and expression, with low to no TrkA mRNA expression
associated with poor prognosis. This salient study not only implicated Nmyc in the repres‐
sion of TrkA expression but also reported moderate to high TrkA expression in non-Nmyc
amplified disease. The inverse relationship between Nmyc amplification and expression, low
TrkA expression and advanced stage disease has now been confirmed by many studies, and
it is generally accepted that low TrkA expression combined with Nmyc amplification and
expression  characterises  unfavourable  NB  and  carries  poor  prognosis  [156,  257-270].  In
support of this,  NBs that form in the root ganglia of Nmyc transgenic mice also exhibit
reduced TrkA expression [271]. Nmyc amplified NBs, however, also exhibit heterogeneity
[272] and a small number of these tumours exhibit high TrkA expression and favourable
histology [270], suggesting that the relationship between NMYC and TrkA in NB is not always
straightforward.
Adding to the observation that moderate to high TrkA levels associate with non-Nmyc
amplified NB [257, 258], Shimada and colleagues extended the clinical relationship between
TrkA expression in NB to include outcome, prognostic significance, biological relevance and
histopathological status. They reported that TrkA expression could not distinguish prognostic
groups but could distinguish between Nmyc amplified (low TrkA) and non-Nmyc (high TrkA)
amplified NB, between Nmyc amplified NB with favourable (high TrkA) and unfavourable
(low TrkA) histology, but could not distinguish between non-Nmyc amplified NB with
favourable histology (moderate to high TrkA) and unfavourable histology (moderate to high
TrkA) [270]. This contrasts with some reports [257, 258, 264] but not others [263]. Adult NBs
are aggressive non-Nmyc amplified tumours that express high TrkA levels and in such bear
similarity to non-Nmyc amplified paediatric NBs [156, 268, 273].
Low TrkA expression by Nmyc amplified NBs may relate to an origin along the sympathoa‐
drenal lineage within non-TrkA expressing NCC subpopulations that colonize coalescing
sympathetic ganglia, paraganglia and adrenal medulla anlage during development [225].
Alternatively, reduced TrkA expression in Nmyc amplified NBs may occur post transforma‐
tion, since Nmyc represses TrkA transcription by promoting TrkA promoter methylation and
TrkA promoter methylation is detected in Nmyc amplified NBs [274, 275].
Moderate to high TrkA levels in non Nmyc-amplified NBs may also relate to cellular origin
within undifferentiated TrkA expressing NCC subpopulations of the sympathetic chain and
adrenal primordia [225, 276], or may also occur post-transformation, regulated by NTs, growth
factors and/or cytokines [277-279].
Despite elevated TrkA expression in advanced stage non-Nmyc amplified and in a small
subgroup of Nmyc amplified NBs with favourable histology [270], full length TrkA exhibits a
tumour suppressor function in NB models, suggesting that defects in TrkA receptor signalling
occur in NB [280]. Consistent with this, TrkA gene transfection in the absence of CD271/
p75NTR restores NGF responsiveness to NB cells, inducing either neuronal differentiation,
growth arrest and/or apoptosis in response to NGF [73, 281-284]. Differentiation induced by
NGF in TrkA transfected NB cells involves insulin growth factor II [285], RET [286], c-Src [287],
protein kinase C-ε [288] and Ras/MAPK/Erk signalling [289, 290], and associates with reduced
angiogenic factor expression and angiogenesis resulting in reduced tumorigenic activity [291,
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292]. Furthermore, full length TrkA does not promote genetic instability [73, 293] or invasive
behaviour of NB cells [294]. Apoptosis induced by TrkA in NB cells is p53-dependent [295],
involves the cerebral cavernous malformation 2 protein, CCM2 [296], ERK and caspase-7, and
can also be augmented by NGF [297]. As stated above, TrkA may also acts as a true dependency
receptor, recruiting CD271/p75NTR as a hired killer to promote apoptosis in the absence of NGF
[192]. TrkA responsiveness and specificity for NTs is optimised by CD271/p75NTR, which in its
own right acts as a Fas-like apoptosis receptor in response to pro-NTs, supporting the
hypothesis that NBs that coexpress TrkA and CD271/p75NTR are favourable tumours that carry
good prognosis [298, 299]. It should be noted, however, that metastatic bone marrow NB
infiltrates induced in SCID mice express TrkA [300] and human NB metastatic bone marrow
infiltrates express CD271/p75NTR [301].
Although, TrkA gene rearrangements have not been described in NB, a c.1810 C>T TrkA
polymorphism has been detected in approximately 9% of NB, with potential to predict disease
relapse in non-Nmyc amplified NB [302].
6.2. The alternative TrkAIII splice variant in NB
Anomalies of TrkA expression that do not support an exclusively tumour suppressing role
for TrkA in NB, include moderate to high TrkA expression reported in non-Nmyc ampli‐
fied advanced stage, metastatic unfavourable NBs. These reports may be explained by TrkAIII
expression [73], an increase in which was originally reported in advanced stage NB [73], and
later confirmed [156, 303, 304]. Recently, TrkAIII expression in a cohort of 500 NBs was found
to be significantly higher in high TrkA expressing unfavourable NBs compared to high TrkA
expressing favourable NBs (p<0.0001) and to correlate with worse prognosis [156]. Further‐
more in the latter study, TrkAIII promoted a cancer stem cell NB phenotype [156], helping
to explain high TrkA levels in unfavourable non-Nmyc amplified NB, adult NB and a subset
of relapsing NBs [73, 156, 270, 303, 304]. In support of this, gene-based outcome prediction
studies  focussed on  exon-specific  expression,  have  identified  a  TrkA splicing  difference
between stage I and stage IV non-Myc amplified NBs [305, 306], and an exon gene array
analysis using TrkAI/II specific primers, excluding TrkAIII, reported to provide a signifi‐
cant prognostic and predictive statistical advantage, associating high TrkAI/II  expression
with better prognosis in NB [307].
TrkAIII represents a developmental and stress-regulated TrkA isoform [73, 77] that exhibits
spontaneous ligand-independent activation and oncogenic activity in NB models [73, 78, 79]
and promotes a nestin, CD117, CD133 and Sox2 positive NB stem cell phenotype [156]. In
contrast to full length TrkA, TrkAIII does not restore NGF responsiveness to NB cells nor
induce NB cell differentiation or apoptosis [73, 78, 79] but interfers with NGF/TrkA signalling
through Ras/MAPK, augments genetic instability by promoting centrosome amplification [79]
and promotes angiogenesis by altering the equilibrium between MMP-9, VEGF and throm‐
bospondin, through IP3K/Atk. Together these phenomena promote NB cell xenograft primary
[73] and metastatic tumorigenic activity [308]. Furthermore, TrkAIII increases NB cell resist‐
ance to stress, doxorubicin and geladanamycin-induced cytotoxicity [73, 78, 79].
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TrkAIII expression in human NB cells is regulated by hypoxic stress [73] and by agents that
promote stress within the endoplasmic reticulum (unpublished observations). TrkAIII
signalling through IP3K/Akt but not Ras/MAPK, combined with interference in NGF/TrkA
signalling, would permit tumours to override NT-dependence, whilst promoting survival and
staminality to provide a selective advantage [73, 78, 79]. Therefore, TrkAIII expression in non-
Nmyc amplified NBs may parallel the selective advantage provided by BDNF/TrkB in Nmyc
amplified NBs [309-313], and NT-3/TrkC in a subgroup of advanced stage NBs [314].
It remains to be determined whether TrkAIII can counteract the pro-apoptotic effects of the
Sortlin-CD271/p75NTR complex in the presence of pro-NTs or prevent CD271/p75NTR-mediated
apoptosis in the absence of NTs.
6.3. CD271/ p75NTR expression in NB
The CD271/p75NTR low affinity nerve growth factor receptor is a neural crest stem cell marker
[249, 250, 315] and is expressed by neural crest-derived melanoma and NB cancer stem cells
[250, 316, 317]. In a model of non-Nmyc amplified NB cancer staminality, self replicating
CD133, CD271/p75NTR positive clonogenic stem cells produce both a non-malignant fibromus‐
cular lineage and a malignant neuronal (N)-type cell lineage defective in terminal neuronal
differentiation. Although Trk expression in this NB population remains to be determined,
CD271/p75NTR positive self-replicating neural stem cells have been shown to express TrkA,
TrkAIII, TrkB and TrkC [73, 318].
Consistent with a restricted pattern of CD271/p75NTR expression in NB, primary human NBs
have been reported to not express CD271/p75NTR [252, 259, 319] or to express variable levels of
CD271/p75NTR [251, 319], which either correlate [259] or don’t correlate with TrkA expression
[259, 264]. Indeed, differences in CD271/p75NTR co-expression with TrkA have been associated
with survival, with the co-expression of CD271/p75NTR and TrkA in NB associated with a 100%
survival probability, TrkA expression in the absence of CD271/p75NTR with a 62.3% (inter‐
mediate) survival probability and no TrkA or p75NTR expression with a 0% probability of
survival [259]. Consistent with this, a lack of CD271/p75NTR expression has been reported in
Nmyc amplified and undifferentiated NB [252, 319, 321] and high CD271/p75NTR expression
reported in more favourable differentiating NBs, ganglioneuromas and ganglioneuroblasto‐
mas [251, 252, 299, 320]. However, despite the general concept that high level CD271/p75NTR
expression associates with favourable NB behaviour and outcome [259, 264, 322], CD271/
p75NTR expression characterises GD2 positive stage IV metastatic bone marrow NB infiltrates
[301] and aggressive adult NBs [268, 323].
Consistent with a general association with favourable NB, CD271/p75NTR exhibits a tumour
suppressor role in NB models, promoting differentiation, apoptosis and reducing tumorigenic
activity [299, 324, 325]. Differentiation promoted by CD271/p75NTR depends upon the molec‐
ular context and may involve an IP3K-Akt-mediated BcL-X-dependent survival pathway [326,
327] or a TrkA-dependent pathway, in which CD271/p75NTR plays a subtle but critical role in
optimising and prolonging NGF-mediated TrkA activation [328-331]. Indeed, mutation of
CD271/p75NTR within a TrkA context results in proliferation and not differentiation in response
to NGF [332]. Coexpression studies in NB cells have also indicated that, in response to NTs,
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CD271/p75NTR alone induces mild differentiation, TrkA alone causes a more marked differen‐
tiation and coexpression an even more marked and rapid differentiation [333].
CD271/p75NTR can acts as either an anti-apoptotic or pro-apoptotic factor, depending upon
the molecular context. At low TrkA to CD271/p75NTR ratios the anti-apoptotic activity of NGF
requires binding to CD271/p75NTR, whilst at higher TrkA to CD271/p75NTR ratios involves a
mechanism  independent  of  CD271/p75NTR  binding  [334].  Conversely,  NGF  also  induces
apoptosis in NB cells with a high CD271/p75NTR to TrkA ratios [335]. In the absence of NTs
and  TrkA,  CD271/p75NTR  induces  apoptosis  and  inhibits  NB  tumorigenic  activity  [299,
336-338].  It  has  been  reported  that  apoptosis,  induced  by  non-ligated  CD271/p75NTR  is
inhibited  by  non-ligated  TrkA  but  this  may  reflect  spontaneous  activation  of  overex‐
pressed TrkA [337]. Furthermore, agents such as prion proteins activate CD271/p75NTR  to
promote apoptosis in NB cells via NF-κB [339]. In the absence of spontaneous TrkA activation
and NT expression, however, the coexpression of CD271/p75NTR and TrkA promotes more
marked  apoptosis  [333].  In  the  presence  of  BDNF  CD271/p75NTR  interaction  with  TrkB
promotes NB cell proliferation and survival, through RAS/MAPK and PI3K/AKT/NF-κB [322].
These reports suggests that CD271/p75NTR is a pivotal regulator of the disparate behaviour
of  TrkA  and  TrkB  expressing  NBs,  exhibiting  capacity  to  enhance  differentiation  and
apoptotic responses in TrkA expressing NBs and enhance proliferation and survival responses
in TrkB expressing NBs, by increasing receptor sensitivity to low NT concentrations and
blocking responses to promiscuous NTs.
CD271/p75NTR also interacts with Sortilin and other proteins, complicating potential responses
to both pro- and active NTs. The CD271/p75NTR-Sortilin co-receptor complex augments affinity
for proNGF and induces apoptosis [105, 340]. Furthermore, CD271/p75NTR also interacts with
NRIF, TRAF, NRAGE and MAGE proteins to promote apoptosis [340-342].
With respect to the regulation of CD271/p75NTR expression in NB, Nmyc acts as a transcrip‐
tional repressor of CD271/p75NTR expression by promoting promoter methylation [274]. This
effect can be reversed by HDAC inhibitors,  resulting in the resoration of NGF-mediated
apoptosis [274]. This novel pathway, detected in Nmyc amplified NB, may help to explain
the inverse relationship between CD271/p75NTR  and Nmyc expression detected in human
Nmyc amplified NBs and in root  ganglia  NBs in Nmyc transgenic  mice [271,  343].  The
histone methyltransferase EZH2A has also been reported to repress CD271/p75NTR provid‐
ing an additional Nmyc-independent CD271/p75NTR  transcriptional repressing mechanism
that  may  contribute  to  the  genesis  and  maintenance  of  undifferentiated  CD271/p75NTR
negative NBs [344].
At the therapeutic level, CD271/p75NTR protects NCC and NB cells from apoptosis induced by
antimitotic agents [345], and histone deacetylase inhibitors induce NB cell apoptosis and
restore CD271/p75NTR and TrkA expression [274, 346].
6.4. TrkB and BDNF in NB
Fully spliced TrkB is expressed by a subpopulation of Nmyc amplified NBs [311, 347-349].
Despite observations that Nmyc alone is insufficient to induce TrkB expression [348], TrkB
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expression in NB exhibits a positive correlation with Nmyc amplification and expression [309,
311, 347, 348, 350]. TrkB expression is stimulated by activated c-erbA in NB cells, unveiling a
potential oncogenic receptor tyrosine kinase-mediated mechanism for promoting TrkB
expression [351]. Aggressive unfavourable Nmyc amplified NBs also express BDNF, which
when coexpressed with TrkB provides an autocrine/paracrine survival mechanism in tissues
that do not express NTs [309-313]. Recently, BDNF variants encoding exons 4, 6 and 9 have
been associated with unfavourable NB outcome [312, 313].
TrkB expression by sympathoblasts subpopulations during SNS development provides a
potential origin for TrkB expressing NBs. However, this population proliferates in response
to BDNF in vitro but does express BDNF in vivo [225, 245], suggesting that BDNF expression
may be acquired at a later stage. TrkB transcription in NB cells is also up regulated by hypoxia
inducible factor-1, providing a potential epigenetic mechanism through which tumour-
associated hypoxia could augment TrkB expression [352].
In contrast to signals from NGF-activated TrkA, which induces NB cell differentiation and
growth arrest [73, 324, 353, 354], BDNF activation of TrkB induces partial differentiation in the
absence of growth arrest, through Ret tyrosine kinase [354-357]. BDNF activation of TrkB
increases NB cell survival [358], resistance to chemotherapeutic agents [358-363], augments
invasive capacity [294] in cooperation with c-Met [364] and galectin-1 [365], promotes angio‐
genesis and angiogenic factor expression [292, 350, 366], augments genetic instability [293]
(Schulte et al., 2008) and increases metastatic behaviour by inhibiting anoikis [367]. In contrast,
NB cells expressing truncated TrkB lacking the tyrosine kinase domain, display a more
differentiated phenotype [311] and this receptor is more frequently detected in ganglioneur‐
oblastomas and ganglioneuromas. Consistent with this, truncated TrkB overexpression in NB
cells promotes differentiation suggesting that this receptor variant promotes a more benign
phenotype [368]. Oxidative stress up-regulates the expression of full length TrkB relative to
the truncated isoform, providing an additional epigenetic mechanism for regulating TrkB
involvement in NB [369].
6.5. TrkC and NT3 in NB
TrkC is expressed by migrating NCC progenitors, sympathoblasts and sympathetic neurons
[194, 201, 203], providing many potential origins for TrkC expressing NBs. High level TrkC
expression in low stage NBs is associated with favourable outcome (309, 310, 349, 353, 370-372],
and is often accompanied by TrkA expression [257, 258, 309]. Recently, however, a subset of
advanced stage IV NBs has been identified that exhibit high level NT-3 and TrkC co-expression,
providing an autocrine/paracrine survival and proliferation mechanism for selecting these
NBs in tissues that do not express NT-3 [314]. This expression pattern bears close similarity to
migrating, proliferating NCC sympathoblasts prior to sympathetic neuronal differentiation,
which also coexpress NT-3 and TrkC [194, 201, 203], identifying a potential origin for this NB
subset. TrkC expression in NB, like that of TrkA, inversely correlates with Nmyc amplification
and expression, and Nmyc amplified NBs either do not express TrkC at all, or express truncated
TrkC [371, 372]. With the exception of NBs that coexpress NT3 and TrkC [314], the co-
expression of TrkC, TrkA and CD271/p75NTR in NB carries the best prognosis and associates
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more frequently with spontaneous regression, differentiation and chemo-responsiveness [100,
258, 259, 333, 370, 371]. The TrkC gene, however, encodes multiple NT-3 receptors with distinct
biological properties and substrate specificities [89, 373] and, although TrkC gene rearrange‐
ments in NB have not been reported, the effect of differential TrkC isoform expression in NB
remains to be elucidated.
Association between high TrkC expression and favourable NB outcome, in the absence of NT-3
[333, 371], is consistent with pro-apoptotic TrkC dependency receptor function, which
promotes apoptosis in the absence of CD271/p75NTR and NT expression [191, 192]. Further‐
more, NT-3 activation of TrkC induces NB cell differentiation [374] and the co-expression of
TrkC with CD271/p75NTR lowers tumorigenic potential and tumour growth [375] but may
protect NB cells from doxorubicin and cisplatin cytotoxicity [375].
With respect to the transcriptional regulation of TrkC, Nmyc silencing increases TrkC expres‐
sion in human NB cells [376], corroborating the inverse relationship reported for TrkC
expression and Nmyc amplification [371,372]. TrkC expression, furthermore, is abrogated by
the activation of c-erbA, providing a potential oncogenic tyrosine kinase-mediated mechanism
for repressing TrkC expression in NB [351]. Retinoic acid induces TrkC expression in human
NB cells, restoring NT-3-dependent differentiation [152]. Retinoids also induce the expression
of microRNAs-9, 125a and 125b that repress truncated kinase domain-deleted TrkC, resulting
in altered growth and highlighting a role for the truncated TrkC receptor in the regulation of
NB growth and differentiation [377]. MiR-151-3p represses full length TrkC expression,
whereas miRs-128, 485-3p, 765 and 768-5p repress truncated TrkC expression in NB cells [378],
indicating that full length and truncated TrkC receptors are regulated by different miRs,
linking NT-mediated processes to miR expression in NB.
6.6. General considerations on NT and NTR expression patterns in NB
The concept that different NT and NTR receptor expression profiles characterise NB subsets
and that these differences are involved in divergent NB behaviour and therapeutic suscepti‐
bility, continues to evolve with potential to improve prognosis and therapeutic choice, whilst
identifying novel potential therapeutic targets.
The hypothesis that high TrkA, high TrkC and/or high CD271/p75NTR expression always
associate with low disease stage and better prognosis in NB is clearly not the case. Moderate
to high levels of TrkA, TrkC and/or CD271/p75NTR can also characterise advanced stage and
relapsing non-Nmyc amplified NBs and a subset of Nmyc amplified NB with favourable
histology (see section 6.1). However, high TrkB expression appears to distinguish advanced
stage Nmyc amplified from non-Nmyc amplified NB and carries poor prognosis associated
with potential therapeutic resistance (see section 6.4). It is also now apparent that NTRs can
be expressed as different isoforms with altered biological activity and can interact with one
other and with a variety of ancillary proteins to modulate function (see section 6.3), compli‐
cating prognosis and potential therapeutic outcome, as outlined below (Fig. 9).
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Figure 9. Different combinations, potential outcomes and prognosis of NTs and NTRs in NB
NTR expression in low stage non-Nmyc amplified NB characterised by the coexpression of
TrkA and CD271/p75NTR may carry the best prognosis. These tumours may terminally
differentiate in response to NGF (TrkAI) or NT-3 (TrkAII), or undergo TrkA and/or CD271/
p75NTR–mediated apoptosis in the absence of NTs, depending upon the CD271/p75NTR to TrkA
expression ratio. Furthermore, the coexpression of Sortilin in these tumours would extend
apoptotic potential to include pro-NTs (see Sections 4.2.1-4.2.4). NBs that express TrkA but not
CD271/p75NTR may have a worse prognosis, as they require higher NT concentrations for TrkA
activation and signalling and would also respond to promiscuous NTs potentially with a
response of proliferation, survival and/or partial differentiation. In the absence of CD271/
p75NTR, these NBs would neither exhibit TrkA dependency receptor-mediated apoptosis nor
Sortilin-CD271/p75NTR complex-mediated apoptosis in response to pro-NTs.
NBs that co-express TrkC and CD271/p75NTR but not TrkA or TrkB, may have better prognosis
with potential to differentiate in response to NT-3 but alternatively could proliferate and
survive in response to NT-3, complicating prognosis. NT-3 is rarely expressed in NBs,
increasing the potential for TrkC dependency receptor-mediated apoptosis, in the presence or
absence of CD271/p75NTR (see Sections 4.5 and 6.3). The coexpression of Sortilin with
CD271/p75NTR in these NBs would increase apoptotic potential to include a response to pro-
NTs (see Sections 4.2.3 and 6.3). Advanced stage NBs coexpressing TrkC and NT-3 would be
expected to carry worse prognosis as a result of this autocrine survival and proliferation
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mechanism that may also extend to NBs expressing TrkC but not NT-3 in tissues that express
NT-3, and could be further optimised by co-expression of CD271/p75NTR (see Section 6.3).
High levels of BDNF and TrkB expression in Nmyc-amplified NBs, in the absence of TrkA,
TrkC and CD271/p75NTR, carries the worse prognosis as a result of autocrine/paracrine BDNF-
mediated TrkB activation, which would be expected to promote proliferation, survival and
metastatic capacity. Furthermore in the absence of BDNF, TrkB would not be expected to
promote apoptosis, as TrkB does not act as a dependence receptor (see Sections 6.4). As with
other Trk receptors, TrkB co-expression with CD271/p75NTR would be expected to optimise
NT-specificity and responsiveness, which would be expected to further promote aggressive
bahaviour in TrkB expressing NBs.
NBs that express CD271/p75NTR but not Trks may carry better prognosis, as they would be
expected to respond to active NTs with an apoptotic response and if co-expressed with Sortilin
in the absence of Trks, would also be expected to exhibit an apoptotic response to pro-NTs,
which comprises up to 50% of secreted NTs (see Sections 4.2.2 and 6.3).
Non-Nmyc amplified NBs that express TrkAIII may carry worse prognosis, as spontaneous
TrkAIII activation would override NT-dependency, provide a selective growth advantage in
tissues including those that do not express NTs, promote NB cell stamilality, survival,
angiogenesis and genetic instability, resulting in a more tumorigenic, metastatic and stress-
resistant phenotype (see Sections 4.2.1 and 6.2). Although it remains to be elucidated whether
TrkAIII may interfere with CD271/p75NTR –mediated apoptosis in the presence or absence of
Sortilin, its expression in NB may represent the biological equivalent to BDNF/TrkB expression
in Nmyc amplified NB and TrkC/NT3 expresssion in a subset of advanced stage NBs, as an
indicator of poor prognosis.
7. Potential therapeutic approaches
7.1. Trk kinase inhibitors
Trk kinase inhibitors would be more suitable for use in advanced stage Nmyc amplified TrkB
expressing NBs and advanced stage unfavourable non-Nmyc amplified NBs that express the
TrkAIII oncogene but may also reduce survival in NBs expressing full length TrkA and TrkC
and their corresponding NTs.
Therapeutic Trk kinase inhibitors include the selective Trk kinase inhibitors AZ-23 and AZ623,
which inhibit Trk kinase activity at low nanomolar concentrations. AZ-23 has shown efficacy
following oral administration in a TrkA-driven mouse allograft NB model [379], whereas
AZ623 inhibits BDNF-mediated signalling and NB proliferation, and when combined with
topotecan prolongs the inhibition of tumour regrowth and reduces chemo and radio thera‐
peutic resistance [380, 381]. Lestaurtinib (CEP-701) is a small-molecule receptor tyrosine kinase
inhibitor that competitively inhibits ATP binding to the Trk kinase domain at nanomolar
concentrations. This compound not only inhibits the tyrosine kinase activities of full-length
Trk receptors but also inhibits the kinase activity of the alternative TrkAIII splice variant [73,
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78,79]. Lestaurtinib inhibits NB growth in vitro and in vivo, and substantially enhances the
efficacy of conventional chemotherapy, such as 13-cis-retinoic acid, ferenteride and bevacizu‐
mab, presumably by inhibiting autocrine TrkB/BDNF [382-384] and/or spontaneous TrkAIII
activity [73]. Lestaurtinib is an active metabolite of the Trk kinase inhibitor CEP-751, and is
more suitable for clinical trials, as it can be administered orally [384, 385]. These Trk tyrosine
kinase inhibitors not only target tumour promoting effects of Trk receptor activation but also
Trk-mediated chemotherapeutic resistance, which has been attributed not only to TrkB [348,
358-363] but also to TrkC [375], fully spliced TrkA [375] and TrkAIII [73, 78, 79]. CEP-701
synergises with retinoids in the treatment of NB by inhibiting TrkB activity [386].
Nifutimox, a drug used for years to treat Chagas disease, is also currently in clinical trials for
refractory or relapsed NB, and has been shown to suppress TrkB-mediated Akt activation and
induce caspase-dependent apoptosis of NB cells in vitro and in vivo [387].
7.2. TrkAIII inhibitors
Tyrosine kinase inhibitors K252a and CEP-701 inhibit TrkAIII tyrosine kinase activity. TrkAIII
activity is also inhibited by the Hsp90 inhibitor geladanamycin and its clinically relevant
analogues 17-AAG and 17-DMAG, and by the ARF inhibitor Brefeldin A (BFA) [78, 79]. CEP701
inhibits TrkAIII activity and TrkAIII-induced centrosome amplification at nanomolar concen‐
trations, whereas BFA reversibly inhibits spontaneous TrkAIII activation in association with
disruption of the Golgi Network and the endoplasmic reticulum/Golgi Network intermediate
compartment [78, 78]. Geldanamycin and its analogues reversibly inhibit TrkAIII tyrosine
kinase activity and reduce proliferation of TrkAIII expressing NB cells in vitro [78]. Inhibitors
of TrkAIII activity, however, do not inhibit TrkAIII expression nor promote TrkAIII elimina‐
tion but cause retention within the endoplasmic reticulum, with potential to induce an ER
stress response. This may help to explain the high level of resistance to GA-mediated cytotox‐
icity exhibited by TrkAIII but not TrkAI transfected NB cells, despite inhibition of TrkAIII
activity [78, 79]. This suggests that, in addition to other off target effects, reversible TrkAIII
tyrosine kinase inhibitors may increase stress-resistance by promoting TrkAIII-ER retention
and inducing an ER stress response. Consistent with this, geldanamycin selects slow growing
TrkAIII expressing NB cells from mixed populations, with TrkAIII re-activation post drug-
removal, suggesting a mechanism for potential post therapeutic relapse [78]. To counter this,
we have also developed a specific peptide nucleic acid (PNA) inhibitor of TrkAIII expression
based upon the novel exon 5/8 splice junction (TrkAIII PNA conjugate (KKAA)4-GGCCGGGA‐
CAC) [78, 79] for use in combination with with TrkAIII tyrosine kinase inhibitors, to maximise
therapeutic efficacy.
7.3. Agents that conserve Trk tyrosine phosphorylation and facilitate signal transduction
TrkA activation and signal transduction is fundamental for NB differentiation and the loss of
TrkA expression or defective activation and/or signalling probably contributes to NB patho‐
genesis. Agents that optimise TrkA activation and facilitate subsequent signal transduction
may, therefore, overcome defective TrkA signalling and restore differentiation and/or
apoptotic responses to NTs. In this context, a novel cyclophane compound CPPy, with low
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toxicity, has been shown to facilitate NGF-induced TrkA signal transduction through RAS/
MAPK and to induce NB differentiation [388]. Since, CD271/p75NTR optimizes TrkA responses
to NTs and augments NT specificity, agents such as CPPy may be particularly useful in NBs
that express TrkA but not CD271/p75NTR.
7.4. DNA methylation and HDACs inhibitors
Recent reports have identified promoter methylation as an important mechanism in the
transcriptional repression of TrkA and CD271/p75NTR in NB [274, 389, 390]. Therapies that
reverse or inhibit DNA methylation may, therefore, be useful in malignant NBs to restore the
expression of favourable NB genes. In support of this, the DNA methylation inhibitor 5-aza-2’-
deoxycytidine and histone deacetylase inhibitors 4-phenylbutyrate, trichostatin A and
Romidepsin, have been shown to restore TrkA and CD271/p75NTR expression in NB cells,
decrease proliferation, reduce tumorigenicity and promote caspase-dependent apoptosis [291,
346, 390]. Romidepsin is presently in clinical trials [346].
7.5. Liposome targeting of TrkB expressing cells
Considering the importance of TrkB in advanced stage Nmyc amplified NB, a recent report
has characterised liposomes that target TrkB expressing cells, providing the opportunity to
deliver nanotherapeutic cargos to TrkB expressing cells within NBs [392].
8. Concluding remarks
The complex nature of NT and NTR expression during normal development of the sympathetic
nervous system is reflected in the different patterns of NT and NTR expression exhibited by
human NB, which is consistent with their NCC origin at different stages along the differenti‐
ating sympathoadrenal lineage. The different biological potentials of TrkA, TrkB, TrkC,
CD271/p75NTR and Sortilin receptors expressed alone or in different combinations, range from
promotion of proliferation and/or differentiation to survival and/or apoptosis and to chemo‐
therapeutic resistance. This complexity is increased by the potential of each receptor to be
expressed as a functionally altered alternative splice variant, the recent characterisation of
TrkA and TrkC as true dependency receptors, and the pro-apoptotic behaviour of the CD271/
p75NTR -Sortilin complex, providing an exciting array of new potential ways to restore and/or
modulate Trks, CD271/p75NTR and Sortilin behaviour for therapeutic purposes, based upon
accurate characterisation of NT and NTR expression profiles in individual tumours.
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